Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
January 10, 2022 (Issue: 1641)
The FDA has issued an Emergency Use Authorization
(EUA) for the investigational long-acting monoclonal
antibodies tixagevimab and cilgavimab (Evusheld –
AstraZeneca) to be administered concomitantly by IM
injection for pre-exposure prophylaxis...more
- FDA News Release. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. December 8, 2021. Available at: https://bit.ly/3saed1U. Accessed December 16, 2021.
- Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19. Med Lett Drugs Ther 2021; 63:163.
- Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19. Med Lett Drugs Ther 2021; 63:130.
- K Dooling. Evidence to recommendations framework: an additional dose of mRNA COVID-19 vaccine following a primary series in immunocompromised people. Advisory Committee on Immunization Practices meeting, August 13, 2021. Available at: https://bit.ly/2Uqqy3H. Accessed December 16, 2021.
- CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. December 10, 2021. Available at: https://bit.ly/38i7CIH. Accessed December 16, 2021.
- In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons. Med Lett Drugs Ther 2021; 63:145.
- Booster doses of COVID-19 vaccines. Med Lett Drugs Ther 2021; 63:186.
- FDA News Release. Coronavirus (COVID-19) update: FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds. December 9, 2021. Available at: https://bit.ly/3GClETN. Accessed December 16, 2021.
- FDA. Fact sheet for health care providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). December 2021. Available at: https://bit.ly/3IWpQjg. Accessed December 21, 2021.
- AstraZeneca. Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study. December 16, 2021. Available at: https://bit.ly/3Jluk3d. Accessed December 21, 2021.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
